CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas

Inclusion Criteria: 1. Patients with willingness to be in the study and follow all study procedures, and capable of providing informed consent 2. Male or female aged 18-70 years; 3. Patients with unresectable, locally advanced or metastatic relapse/refractory sarcomas that have failed at least the front line standard treatment confirmed by histology or cytology; 4. At least one measurable lesion, i.e. the length of non-lymph node lesions examined according to CT cross-sectional scanning or magnetic resonance imaging (MRI), or the short diameter of the lymph node lesions is ≥15 mm according to RECIST 1.1, and the FDG PET signal from the measurable lesion is \> 3 SUV; 5. Tumors with AXL positive (IHC 1+ or greater) in ≥50% of all tumor cells. A new biopsy is required if the sample is over one year. 6. ECOG Performance Status 0-1; 7. Expected survival greater than 12 weeks; 8. Adequate organ and hematopoietic system functions to meet the following requirements: * Hemoglobin (HGB) s 90 g/L, no blood transfusions within two weeks; * White blood cell (WBC) count≥2.5×109/L； * Absolute Neutrophil Count (ANC) ≥1.5×109/L; * Platelet (PLT) count ≥80×109/L; * Total bilirubin (TBIL) ≤3.0ng/dL or ≤5 ULN; * ALT and AST ≤5 ULN; for liver metastasis, ALT and AST ≤5 ULN * Creatinine (Cr) ≤1.5 x ULN; or creatinine removal rate (CrCl) ≥50 mL/min; 9. PT: INR \< 1.7 or extended PT to normal value \< 4s 10. Normal language, recognition and consciousness assessed by investigator during screening phase; 11. Capable of receiving treatment and follow-up, including treatment in the clinical center; Exclusion Criteria: 1. Females with pregnancy or in lactation period; 2. Subjects with active hepatitis B, or active hepatitis C. Subjects with undetectable HBV DNA or HCV RNA after anti-virus treatment can be enrolled; 3. HIV positive; 4. Other active infections of clinical significance; 5. Subjects with the following previous or accompanying diseases: • Subjects diagnosed as severe autoimmune diseases that require long term (more than 2 months) treatment with systemic immunosuppressants (steroids), or diseases with immune-mediated symptoms, including ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus (SLE), and autoimmune vasculitis (e.g. Wegena granuloma); 6. Patients with previous diagnosis as motor neuron disease caused by autoimmunity; 7. Patients previously suffered from toxic epidermal necrolysis (TEN) 8. Patients with any mental illness, including dementia, mental changes, which may cause difficulties understanding the informed consent and related questionnaires; 9. Patients with serious uncontrollable diseases, which may interfere with the therapies in this study; 10. Patients with other active malignancies in the past 5 years excluding those with completely cured basal or squamous skin cancers, superficial bladder cancers or primary breast cancers without need of follow-up treatment; 11. Subjects receiving systemic steroids or steroid inhalants; 12. Patients who have received tumor immunotherapy (including monoclonal antibody against PD-1, PD-L1, PD-L2, CD137 or CTLA-4, or cell therapy) in the past 4 weeks; 13. Subjects allergic to immunotherapies or related drugs; 14. Patients with metastatic lesions in meninges or central nervous system, or clear evidence of central nervous system diseases with continuous significant symptoms in the last 6 months; 15. Patients with NYHA class II heart failure, or hypertension incontrollable by standard care, or medical history of myocarditis, or heart attack within a year; 16. Subjects who have received or are going to receive organ transplantation; 17. Patients with active bleeding; 18. Patients with incontrollable pleural or abdominal fluid that needs clinical treatment or intervention; 19. Patients as determined by the investigators to be inappropriate for the study.